Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.

ABSTRACT:

Background

Inhibition of Nod-like receptor protein 3 (NLRP3) inflammasome within the central nervous system (CNS) is a promising therapeutic target for the treatment of Parkinson's disease (PD).

Objectives

This phase 1b open-label study was conducted in elderly healthy volunteers (HV) and PD patients. The study was designed to assess safety and tolerability and to evaluate the central and systemic pharmacokinetic profile and anti-inflammatory effects of a total daily dose of 300 mg NT-0796 (oral 150 mg suspension capsule formulation every 12 h).

Methods

Four elderly HV and 10 subjects with PD received 150 mg open-label NT-0796 every 12 h for either 7 or 28 days, respectively. Blood and cerebrospinal fluid (CSF) were collected via serial sampling or lumbar punctures fo

SUBMITTER: Clarke N 

PROVIDER: S-EPMC12553988 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature